Sugammadex-induced bronchospasm: a case report
Journal of Dental Anesthesia and Pain Medicine
; : 287-291, 2023.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-1000890
Responsible library:
WPRO
ABSTRACT
Sugammadex has shown faster reversal of steroidal neuromuscular blockade (NMB) than neostigmine, a traditional reversal agent for NMB, even in the intense block phase. This efficiency is possible because of the unique mechanism of action by encapsulating the NMB molecules. Therefore, with the use of sugammadex, we can also expect to avoid direct interactions with the cholinergic system and its subsequent side effects, which are disadvantages of traditional drugs. However, despite these benefits and US Food and Drug Administration (FDA) approval in 2015, rare adverse events associated with sugammadex have been reported. Herein, we report a case of bronchospasm that developed immediately after sugammadex administration.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
English
Journal:
Journal of Dental Anesthesia and Pain Medicine
Year:
2023
Document type:
Article